Sio Gene Therapies Inc.

OTCPK:SIOX Stock Report

Market Cap: US$34.8m

Sio Gene Therapies Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sio Gene Therapies.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?

Oct 19
Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?

Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

Jun 27
Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

My Favorite Stock For 2022: Sio Gene Therapies

Dec 27

Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure

Oct 25

We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely

Sep 28
We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely

Sio Gene Therapies EPS beats by $0.12

Jun 09

Sio Gene Therapies: Gene Therapies For Neurodegeneration

May 28

We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully

May 07
We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully

Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?

Mar 04
Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?

Sio Gene Therapies secures $11.6M from sale of Arvelle Therapeutics

Feb 04

What Is The Ownership Structure Like For Sio Gene Therapies, Inc. (NASDAQ:SIOX)?

Jan 28
What Is The Ownership Structure Like For Sio Gene Therapies, Inc. (NASDAQ:SIOX)?

Sio Gene Therapies to sell Arvelle stake to Angelini Pharma

Jan 04

Here's Why We're Watching Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

Dec 24
Here's Why We're Watching Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

Sio Gene Therapies soars 45% on positive AXO-AAV-GM1 data in nerve cell disorder

Dec 16

Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?

Nov 19
Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?

Axovant on go with pivotal study of gene therapy for rare inherited lipid disorders

Nov 09

Axovant sees delayed enrollment in Parkinson’s study with gene therapy

Oct 29

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sio Gene Therapies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:SIOX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2022N/A-29-37-37N/A
9/30/2022N/A-50-53-52N/A
6/30/2022N/A-68-57-56N/A
3/31/2022N/A-72-61-60N/A
12/31/2021N/A-62-53-53N/A
9/30/2021N/A-47-44-43N/A
6/30/2021N/A-36-46-46N/A
3/31/2021N/A-32-47-47N/A
12/31/2020N/A-46-55-54N/A
9/30/2020N/A-49-57-56N/A
6/30/2020N/A-53-63-63N/A
3/31/2020N/A-73-68-67N/A
12/31/2019N/A-65-62-61N/A
9/30/2019N/A-85-82-82N/A
6/30/2019N/A-105-91-91N/A
3/31/2019N/A-129-134-134N/A
12/31/2018N/A-145-157-157N/A
9/30/2018N/A-169-171-170N/A
6/30/2018N/A-204-206-204N/A
3/31/2018N/A-222-195-190N/A
12/31/2017N/A-249-202-198N/A
9/30/2017N/A-239-184-180N/A
6/30/2017N/A-212-144-141N/A
3/31/2017N/A-181-112-112N/A
12/31/2016N/A-158-95-94N/A
9/30/2016N/A-173N/A-80N/A
6/30/2016N/A-146N/A-67N/A
3/31/2016N/A-133N/A-53N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SIOX's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if SIOX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if SIOX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SIOX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SIOX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SIOX's Return on Equity is forecast to be high in 3 years time


Discover growth companies